Navigation Links
DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
Date:1/10/2012

GAITHERSBURG, Md., Jan. 10, 2012 /PRNewswire-iReach/ -- DFH Pharma, Inc., (DFH) a privately held specialty pharmaceutical company focused exclusively in the HIV-1 therapeutic space, announced today a collaborative agreement between DFH and the National Cancer Institute (NCI) to further the development of the next generation of HIV maturation inhibitor drugs. Maturation inhibitors are a novel class of antiretroviral drug candidates that inhibit HIV-1 replication by interfering with the maturation of the HIV-1 virus.

The collaboration will involve extending successful efforts by DFH Pharma to identify drug candidates with potent activity against all HIV strains, including those that proved resistant to the first-in-class maturation inhibitor, bevirimat. DFH scientists have identified a series of 2nd generation maturation inhibitors with the broad anti-viral activity profile necessary for successful HIV drug development. The NCI investigators will evaluate the activity of these compounds against HIV strains associated with reduced bevirimat activity. The most potent of these compounds will be selected for further pre-clinical testing with a goal of initiating human clinical trials with one or more candidate molecules in the near future.

Dr. Eric Freed, an internationally recognized leader in the field of HIV assembly and release, will head the NCI group. Dr. Freed has worked in the maturation inhibition area since the early 2000's when his group collaborated with Panacos Pharmaceuticals in the discovery and characterization of the maturation inhibitor class of HIV drugs. "We are very excited to be working with Dr. Freed and his NCI colleagues in developing this new class of drugs to treat HIV infection"' said Carl Wild, Ph.D., President and CEO. Dr. Wild continued, "The NCI collaboration will allow DFH to build on its recent success in identifying broadly active maturation inhibitor drug can
'/>"/>

SOURCE DFH Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
2. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
3. Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
4. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
5. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
6. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
7. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... FL (PRWEB) May 26, 2015 ... Inc. have announced plans for the company’s first cellular ... 2015, followed by a full day, hands-on stem cell ... by J. Victor Garcia Gimenez, M.D., President of Therapeutic ... the medical community’s increasing interest in regenerative medicine and ...
(Date:5/26/2015)...  A simple blood test developed at the University ... Alzheimer,s disease is a step closer to being used ... that are needed before a blood test could be ... & Dementia . The guidelines establish protocols and reflect ... includes UNT Health Science Center. "If we ...
(Date:5/26/2015)... mája 2015 Kevin Xu , ... prezidentom Barackovi Obamovi a Billovi Clintonovi za ich ... Dr. Rongxiang Xu , otca Kevina. ... Dr. Xu bol pionier, inovátor, humanitárny pracovník ... v oblasti vedy a príkladné vedenie svojej komunity ...
(Date:5/26/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... the development of oral drug delivery systems, announced today ... company,s Phase IIb trial of ORMD-0801, its oral insulin ... The submission was made under the company,s existing Investigational ... study of ORMD-0801 for type 2 diabetics is designed ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... the leading online,information source for life science ... launched the 2nd Edition of the Southern ... science community of the Southeastern,United States. The ... that constitute the dynamic biopharmaceutical industry in ...
... Celgosivir 4-Week Viral Kinetics Study Data on ... Monday December 3, ... Inc.,(TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases, ... at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results ...
... NOLabs AB, the Swedish,medtech company developing innovative ... Technology, today reported that it has,achieved another ... new line of,products for wounds infected by ... a bacterium that is particularly,troublesome in hospital-acquired ...
Cached Biology Technology:BioSpace Launches 2nd Edition of Southern Pharm(TM) Hotbed Campaign 2MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria 2
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... stem cell research journals? This question has been ... Department of Neurosurgery and Brain Repair at the University of ... Stem Cell Reviews and Reports . Both Sanberg ... being published in the proliferating stem cell journals. ...
... herd of cattle is more than just cows. It,s a ... and hedge against drought. For many smallholder farmers, the loss ... Yet a grievous number of cattle in sub-Saharan Africa ... $40 billion, some twenty-five percent of the total value of ...
... Spring Harbor, NY -- One of the most tantalizing developments ... of targeted treatments, which have proven highly effective in holding ... for a limited period of time. A team led ... Harbor Laboratory (CSHL), today published results of a study that ...
Cached Biology News:Cow vaccines go vroom 2Cow vaccines go vroom 3New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered 2
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Biology Products: